CBRX News Alert Columbia Laboratories (CBRX) 5.62 12/13/2014

New Post Public Reply Private Reply Replies (0) Message Board

Dec 13, 2014 at 5:21 AM

Columbia Laboratories (CBRX) 5.62 $CBRX

Molecular Profiles To Launch US Strategic Alliance At AAPS
PR Newswire - Thu Oct 30, 7:30AM CDT
Molecular Profiles Ltd., a subsidiary of Columbia Laboratories, Inc., (Nasdaq: CBRX) and Maryland-based Xceleron have announced a collaboration to assist drug developers with improved efficiency during clinical development that will be launched at AAPS in San Diego next week.
CBRX: 5.62 (-0.04)

Columbia Laboratories achieves higher Q3 2014 net income of USD3.7m
M2 - Wed Oct 29, 4:48AM CDT
Pharmaceutical company Columbia Laboratories (NasdaqCM:CBRX) on Tuesday reported that its net income was USD3.7m, or USD0.34 per diluted share, for the three month periods ended 30 September 2014.
CBRX: 5.62 (-0.04)

Columbia Laboratories' (CBRX) CEO Frank Condella on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Oct 28, 1:39PM CDT

CBRX: 5.62 (-0.04)

Columbia Laboratories raises guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 1:05PM CDT

CBRX: 5.62 (-0.04)

Columbia Laboratories EPS of $0.34
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 6:18AM CDT

CBRX: 5.62 (-0.04)

Columbia Laboratories Reports Third Quarter 2014 Financial Results
PR Newswire - Tue Oct 28, 6:00AM CDT
Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company"

today announced financial results for the three and nine-month periods ended September 30, 2014.
CBRX: 5.62 (-0.04)

OTC Daily Alert Stock Watch - Columbia Laboratories, Inc. (NASDAQ: CBRX)
WorldStockWire - Sun Oct 19, 12:00AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
CBRX: 5.62 (-0.04)

Columbia Labs reports on October 28
Seeking Alpha - at Seeking Alpha - Wed Oct 15, 9:17AM CDT

CBRX: 5.62 (-0.04)

Columbia Laboratories to Discuss Third Quarter 2014 Financial Results on October 28th Conference Call
PR Newswire - Tue Oct 14, 11:51AM CDT
The management team at Columbia Laboratories, Inc. (Nasdaq: CBRX) will hold a conference call on October 28th, 2014, to discuss financial results for the third quarter ended September 30, 2014. The call details are as follows:
CBRX: 5.62 (-0.04)

Columbia Laboratories' UK Subsidiary To Launch New Development Platform At CPHI
PR Newswire - Wed Oct 01, 7:30AM CDT
Columbia Laboratories, Inc., (Nasdaq: CBRX) today announced that its subsidiary, Molecular Profiles Ltd., is set to unveil the ROADMAP to Clinical Trials platform at the annual CPhI/ICSE Worldwide event in Paris next week, which aims to support companies with the rapid development of both standard and complex drug products.
CBRX: 5.62 (-0.04)

Columbia Laboratories announces George O. Elston as its new CFO
M2 - Thu Sep 25, 7:30AM CDT
Pharmaceutical company Columbia Laboratories (NasdaqCM:CBRX) said on Wednesday that its board has appointed George O. Elston as its chief financial officer.
CBRX: 5.62 (-0.04)

Columbia Laboratories Announces Appointment of New Chief Financial Officer
PR Newswire - Wed Sep 24, 7:30AM CDT
Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company"

, a provider of pharmaceutical development, clinical trial manufacturing, and advanced analytical and consulting services to the pharmaceutical industry, today announced that the Board has named George O. Elston, 50, as Chief Financial Officer, effective October 1. He succeeds Jonathan Lloyd Jones, who is stepping down from the role to pursue other opportunities.
CBRX: 5.62 (-0.04)

Columbia Laboratories Shares Up 6.3% Since SmarTrend's Buy Recommendation (CBRX)
Comtex SmarTrend(R) - Mon Sep 22, 5:22PM CDT
SmarTrend identified an Uptrend for Columbia Laboratories (NASDAQ:CBRX) on August 9th, 2013 at $5.63. In approximately 14 months, Columbia Laboratories has returned 6.31% as of today's recent price of $5.98.
CBRX: 5.62 (-0.04)

Columbia Laboratories to participate in the Rodman & Renshaw 16th Annual Global Investment Conference
PR Newswire - Wed Aug 27, 8:00AM CDT
Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company"

, a provider of pharmaceutical development, clinical trial manufacturing, and advanced analytical and consulting services to the pharmaceutical industry, today announced that it will participate at the upcoming Rodman & Renshaw 16th Annual Global Investment Conference, to be held in New York. The Company will present at the conference at 11:15am on September 9, 2014 at the New York Palace Hotel.
CBRX: 5.62 (-0.04)

Columbia Laboratories reports divestiture of Legatrin's IP and technology to Lil' Drug Store Products for USD2.2m
M2 - Thu Aug 07, 7:13AM CDT
Pharmaceutical company Columbia Laboratories (NasdaqCM:CBRX) reported on Wednesday the sale of the Intellectual Property (IP) Rights and Technology related to Legatrin P.M to Lil' Drug Store Products following exercise of option from a previous agreement.
CBRX: 5.62 (-0.04)

Columbia Laboratories Announces Sale Of IP And Technology For Legatrin P.M. To Lil' Drug Store Products
PR Newswire - Wed Aug 06, 7:30AM CDT
Columbia Laboratories, Inc. (Nasdaq: CBRX) today announced that Lil' Drug Store Products exercised its option to purchase the Intellectual Property Rights and Technology related to Legatrin P.M. Columbia licensed this product to Lil' Drug Store Products approximately fourteen years ago and has received annual royalties. Based on a predetermined formula, Columbia will receive approximately $2.2 million for the sale.
CBRX: 5.62 (-0.04)

Columbia Laboratories posts lower net income of USD0.2m for Q2 2014
M2 - Fri Aug 01, 8:16AM CDT
Pharmaceutical company Columbia Laboratories (NasdaqCM:CBRX) stated on Thursday its net income of USD0.2m, or USD0.01 per diluted share, for the three month period ended 30 June 2014.
CBRX: 5.62 (-0.04)

Columbia Laboratories' Subsidiary, Molecular Profiles, Strikes Alliance With Xenogesis
PR Newswire - Thu Jul 31, 6:00AM CDT
Columbia Laboratories, Inc. (NASDAQ: CBRX) today announced that its subsidiary, Molecular Profiles Ltd., and XenoGesis Ltd., have announced a collaboration that will support pharmaceutical and biotech drug developers during the pre-clinical and formulation development stage. Molecular Profiles' pharmaceutical development services will be supported by XenoGesis' expertise in preclinical drug metabolism and pharmacokinetics (DMPK) to give clients a smarter route into formulation development and a better understanding of a compound's bioavailability. This strategic alliance will allow the Nottingham-based companies to help drug developers in the initial design and selection of compounds for key DMPK and ADME (absorption, distribution, metabolism and elimination) studies, as well as supporting lead candidates which have solubility issues during formulation development.
CBRX: 5.62 (-0.04)

Columbia Laboratories Reports Second Quarter 2014 Financial Results
PR Newswire - Thu Jul 31, 6:00AM CDT
Columbia Laboratories, Inc. (Nasdaq: CBRX) ("Columbia" or "the Company"

today announced financial results for the three and six-month periods ended June 30, 2014.
MRK: 57.72 (-1.62), CBRX: 5.62 (-0.04)

Columbia Laboratories Up 11.8% Since SmarTrend Uptrend Call (CBRX)
Comtex SmarTrend(R) - Fri Jul 25, 9:59AM CDT
SmarTrend identified an Uptrend for Columbia Laboratories (NASDAQ:CBRX) on August 9th, 2013 at $5.63. In approximately 12 months, Columbia Laboratories has returned 11.82% as of today's recent price of $6.29.
CBRX: 5.62 (-0.04)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

$10,000 Boost Fuels Nichols College's Archaeological Quest

Webster First's Generous Contribution It's not every day you see a credit union digging into history—literally. Webster First Federal Credit Union just dropped ten grand to fuel Nichols College's archaeological adventures. This isn't some trivial check to post on Instagram. No, we're talking about funding some serious ground-penetrating radar (GPR) gadgetry that's set...

Palatin Prepares for FY27 Results Amid Market Curiosity

Mark Your Calendars, Investors! Folks grumble about the mundane task of checking fiscal calendars, but without this intel, where are we? On November 17, 2026, Palatin Technologies (NASDAQ:PTN) is slated to release their Q1 Fiscal Year 2027 operating results bright and early, before most of us have even sipped our coffee. The buzz around these numbers is as electric as any...

Understanding Septic Tank Pumping: Insights & Tips

Why in the world are we discussing septic tanks today? Well, it’s because folks often overlook their importance until they’re knee-deep in unexpected plumbing woes. If you're a homeowner, understanding your septic system's needs is crucial to avoid literal and financial messes down the line. Behind the Scenes of Your Septic System Picture your household water usage....

Anderson University Sees Financial Turnaround Success

Anderson University, against all odds, is shaking up the financial narrative they’ve been stuck in for a while. It’s kind of like finding a $20 bill in an old coat—a nice surprise but it doesn’t happen every day. The university’s recent report on their financial progress is reminding folks that when it comes to fiscal discipline, sometimes you just need fresh...

Dana-Farber Integrates IconPCR for Precise cfDNA Sequencing

Innovating Precision in cfDNA Sequencing One day you're trudging along old paths, and the next, technology throws you a curveball that's too critical to ignore. That's the scene at Dana-Farber Cancer Institute with their latest lab upgrade. They've bent the knee to integrate n6's iconPCR system into their toolkit for liquid biopsy research—a move that's caught my...

Bright Idea: Menu Covers Light Up Dining Spaces

Lighting Up Dinner Conversations You ever sit in a restaurant dim enough to make you question if even the chef can see in that darkness? Enter the MENU AID, a nifty brainchild straight out of Chula Vista, California. This invention brings a bright twist to our dining escapades, literally. Picture a menu cover that lights up like it's got its own little halo, solving the...

Procon Uses Robotics to Revamp Cruise Terminal 5

Building Bigger with Robotics at Port Canaveral Robots on a construction site sounds like sci-fi, right? But it's the reality at Port Canaveral's Cruise Terminal 5, where Procon is rolling out its robotic tech magic. This ain't your everyday wrench-and-spanner job; we're talking remote-controlled bots capturing 360-degree images. “Regular reality capture can help teams...

Etavopivat Aims to Tackle Sickle Cell Crisis Head-On

Diving headfirst into the world of sickle cell disease, Novo Nordisk has just thrown its hat in the ring with etavopivat. Now, anyone who's been following the biotech dance knows this ain't no small feat. This investigational therapy is poised to shake things up, offering a new lifeline for those wrestling with this debilitating condition. And leaping from the Phase 3...

Navigating Roof Damage Insurance Claims: Key Insights

No one wants to deal with roof damage, but knowing the rules of the game is half the battle. The landscape of insurance claims can be tricky—especially when Mother Nature starts playing hard ball. Here, we break down what homeowners need to know to stay one step ahead in these situations. Unpacking Roof Damage Coverage Most homeowners think they've got things covered...

CR&R Workers Join Teamsters, Fight for Fair Conditions

Waste Workers Push Back Against Corporate Pressure The Southern California sun isn't the only thing heating up these days; the waste workers at CR&R Environmental Services have cranked up the heat by voting to join Teamsters Local 396. It's like Groundhog Day in the world of labor rights—same story, different locale, workers banding together for a fair shot. A Stand...